Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consequences of targeted treatments for second-line therapy.
De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F. De Maio E, et al. Among authors: minuti g. Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Ann Oncol. 2010. PMID: 20943621 Free article. Review.
Targeted therapy for NSCLC with driver mutations.
Minuti G, D'Incecco A, Cappuzzo F. Minuti G, et al. Expert Opin Biol Ther. 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. Epub 2013 Aug 10. Expert Opin Biol Ther. 2013. PMID: 23930754 Review.
Protein kinase inhibitors to treat non-small-cell lung cancer.
Minuti G, D'Incecco A, Landi L, Cappuzzo F. Minuti G, et al. Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19. Expert Opin Pharmacother. 2014. PMID: 24745764 Review.
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: minuti g. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F. D'Incecco A, et al. Among authors: minuti g. Br J Cancer. 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. Epub 2014 Oct 28. Br J Cancer. 2015. PMID: 25349974 Free PMC article.
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, Cappuzzo F. Vecchiarelli S, et al. Among authors: minuti g. Oncotarget. 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707129 Free PMC article.
40 results